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Abstract
Background: Anxiety and depression are common and treatable risk factors for re-hospitalisation
and death in patients with COPD. The degree of lung function impairment does not sufficiently
explain anxiety and depression. The BODE index allows a functional classification of COPD beyond
FEV1. The aim of this cross-sectional study was (1) to test whether the BODE index is superior to
the GOLD classification for explaining anxious and depressive symptoms; and (2) to assess which
components of the BODE index are associated with these psychological aspects of COPD.
Methods: COPD was classified according to the GOLD stages based on FEV1%predicted in 122 stable
patients with COPD. An additional four stage classification was constructed based on the quartiles
of the BODE index. The hospital anxiety and depression scale was used to assess anxious and
depressive symptoms.
Results:  The overall prevalence of anxious and depressive symptoms was 49% and 52%,
respectively. The prevalence of anxious symptoms increased with increasing BODE stages but not
with increasing GOLD stages. The prevalence of depressive symptoms increased with both
increasing GOLD and BODE stages. The BODE index was superior to FEV1%predicted for explaining
anxious and depressive symptoms. Anxious symptoms were explained by dyspnoea. Depressive
symptoms were explained by both dyspnoea and reduced exercise capacity.
Conclusion: The BODE index is superior to the GOLD classification for explaining anxious and
depressive symptoms in COPD patients. These psychological consequences of the disease may play
a role in future classification systems of COPD.
Background
Chronic obstructive pulmonary disease (COPD) is a pro-
gressive disorder leading to substantial mortality and
morbidity. Treatment goals in COPD are prevention or
deceleration of progression and increasing patients' qual-
ity of life [1]. Apart from physical impairment, patients
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with COPD carry substantial mental burden related to
their disease and its symptoms. Patients frequently suffer
from anxiety [2-7] and depression [2-10]. Both anxiety
and depression are risk factors for rehospitalisation in
COPD [6,7]. Co-morbid depression is associated with
longer hospitalisation stay and poorer survival [9]. Analo-
gously to congestive heart failure [11-14], coronary artery
disease [15] and diabetes [16] psychological disorders are
becoming increasingly recognized as important outcome-
modifying co-morbidities in COPD. Irrespective of
somatic diseases, anxiety and depression themselves are
risk factors of increased mortality [17-19]. While the
mechanisms of these associations are largely unknown,
they are susceptible to therapeutic intervention; treating
major depression in older patients decreases their mortal-
ity [20,21].
Whether the severity of the lung function impairment is
related to anxiety and depression in patients with COPD
has been subject of research. In most studies FEV1 was a
bad predictor of anxiety and depression [2,7,9,10,22].
On the other hand, the presence of respiratory symptoms
causes substantial anxiety and depression [23]. Dyspnoea
has been shown to correlate with anxiety and depression
in patients with COPD [22]. The BODE index (body mass
index, airflow obstruction, dyspnoea, and exercise capac-
ity) is a multistage functional scoring system for COPD
comprising an assessment of symptoms, a surrogate of the
nutritional state, and exercise capacity together with the
spirometric measure of airflow (FEV1) [24]. This multidi-
mensional grading system was shown to be superior over
the FEV1-based GOLD classification [25] for predicting
hospitalization and the risk of death among patients with
COPD [24,26]. Given the incorporation of the subjective
variable 'dyspnoea' and the individual exercise capacity,
the BODE index should be closer related to the individual
subjective consequences of COPD than lung function
alone.
The aim of this study was twofold. First, to test whether
the BODE index is superior to the GOLD classification for
explaining of anxious and depressive symptoms. Second,
to assess which components of the BODE index are asso-
ciated with these psychological aspects of COPD.
Patients and methods
Patient recruitment
This was a prospective cross-sectional study performed at
the Department of Respiratory and Critical Care Medicine
of a primary hospital in Vienna between January 2006 and
May 2007. Adult (≥ 18 yr) in- and out-patients of the insti-
tution were screened for the study. The study was
approved by the Institutional ethics committee and writ-
ten informed consent was obtained from all patients.
Inclusion and exclusion criteria
Inclusion criteria were (1) COPD diagnosed according to
the GOLD consensus [25], (2) Stable conditions i.e.
absence of exacerbation (patients could be recruited dur-
ing exacerbations but were investigated after a stable
period of at least 3 months), (3) ability to perform a six
minute walking test.
Exclusion criteria were (1) absence of informed consent,
(2) insufficient knowledge of German for completing the
questionnaires, (3) unstable coronary artery disease, (4)
history of congestive heart failure, (5) significant pulmo-
nary disease other than COPD (e.g. asthma or lung can-
cer), (6) significant neurological disease.
All together 228 patients were screened, of which 151
were eligible according to the inclusion and exclusion cri-
teria. Of those 122 patients agreed to participate in the
study (response rate 81%).
Classification of COPD
Spirometry was performed according to the ATS/ERS rec-
ommendations [27] using a standard PFT unit (Sensor-
Medics Vmax 22, Viasys Healthcare). Blood gases were
determined in arterialised ear lobe samples using the AVL
Compact 3 Blood Gas Analyzer (Roche Diagnostics, Graz,
Austria). COPD was classified according to the guidelines
of the Global Initiative for Obstructive Lung Disease
(GOLD).
Additionally the BODE index was calculated for classifica-
tion of COPD. The score comprises body mass index
(BMI), post-bronchodilator FEV1%predicted, grade of dysp-
noea (measured by the modified Medical Research Coun-
cil dyspnoea scale, MMRC) and the six-minute-walking-
distance [24]. For calculation of the BODE index, we used
the empirical model as previously described [24]: for each
threshold value of FEV1%predicted, distance walked in six
minutes, and score on the MMRC dyspnoea scale [28], the
patients received points ranging from 0 (lowest value) to
3 (maximal value). For body mass index the values were 0
or 1. The points for each variable were added, so that the
BODE index ranged from 0 to 10 points in each patient.
The post bronchodilator FEV1%predicted was used and clas-
sified according to the three stages identified by the Amer-
ican Thoracic Society [29]. The best of two 6-min walk
tests performed at least 30-min apart [30] was taken as a
surrogate of exercise capacity and was used for scoring.
Variables and point values used for the computation of
the BODE index are shown in table 1. Finally after obtain-
ing the BODE index for all patients, quartiles of the BODE
index were used to construct four severity stages [24,26]:
BODE stage I = BODE index 0 – 2;Respiratory Research 2009, 10:1 http://respiratory-research.com/content/10/1/1
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BODE stage II = BODE index 3 and 4;
BODE stage III = BODE index 5 – 7;
BODE stage IV = BODE index 8 – 10.
Questionnaires
The self-reported hospital anxiety and depression (HAD)
scale was used to screen for psychiatric co-morbidity. The
HAD scale is a validated tool for detecting psychiatric co-
morbidity in patients with somatic disease. It has previ-
ously been applied to COPD patients [2,5-7,9,22]. The
HAD scale consists of seven questions related to anxiety
and seven questions related to depression. Each item is
rated on a 4-point scale, yielding maximum subscale
scores of 21 for anxiety (anxiety score) and depression
(depression score), respectively. Scores on either subscale
of ≥ 8 describe the presence of symptoms suggestive of
depression or anxiety, respectively [6,7,9,31]. The HAD
scale is a screening tool for anxiety and depression but
does not allow a diagnosis of anxiety and depression to be
made.
Statistics
Data on interval scales were described by means± stand-
ard deviations, data on ordinal scales by medians (1st to
3rd quartiles). Normality was assessed using normal plots
and data were transformed as needed. Differences
between means were tested with Student's t-test and
reported with 95% confidence intervals (95%CI). Differ-
ences of the anxiety score and the depression score
between the different stages of disease severity were tested
for by one-way ANOVA. Categorical variables were
described by frequencies and percentages. Differences of
proportions between COPD or BODE stages were com-
pared by the χ2 test for trend. Correlation between ordinal
and interval data was determined by Kendall's rank corre-
lation. Linear regression was used to determine which
components of the BODE were independently associated
with the psychological scores. FEV1%predicted and BMI were
logarithm transformed prior to entry into linear regres-
sion. Collinearity was controlled by means of the variance
inflation factor. Statistics were performed by SPSS 15.0
(Chicago, IL). Significance was accepted at p < 0.05.
Results
Patient characteristics
One hundred twenty two patients were included in the
study. The baseline characteristics of these patients are
Table 1: Variables and Point Values Used for the Computation of 
the Body-Mass Index, Degree of Airflow Obstruction and 
Dyspnoea, and Exercise Capacity (BODE) Index according to 
[24].*
Variable Points on the BODE Index
01 23
FEV1%predicted † ≥ 65 50–64 36–49 ≤ 35
Distance walked in 6 min (m) ≥ 350 250–349 150–249 ≤ 149
MMRC dyspnoea scale‡ 0–1 2 3 4
Body mass index§ >21 ≤ 21
* The cut-off values for the assignment of points are shown for each 
variable. The total possible values range from 0 to 10. FEV1%predicted 
denotes forced expiratory volume in one second as a percentage of 
the predicted value.
† The FEV1%predicted categories are based on stages identified by the 
American Thoracic Society.
‡ Scores on the modified Medical Research Council (MMRC) 
dyspnoea scale can range from 0 to 4; 0 – "Not troubled with 
breathlessness except with strenuous exercise"; 1 – "Troubled by 
shortness of breath when hurrying on the level or walking up a slight 
hill"; 2 – "Walks slower than people of the same age on the level 
because of breathlessness or has to stop for breath when walking at 
own pace on the level"; 3 – "Stops for breath after walking about 100 
yards or after a few minutes on the level"; 4 – "Too breathless to 
leave the house or breathless when dressing or undressing"
§ The values for body-mass index were 0 or 1 because of the 
inflection point in the inverse relation between survival and body-
mass index at a value of 21.
Table 2: Baseline characteristics of the patients sample (n = 
122)*
Characteristics Data
Male/female gender, N/N 68/54
Age, yr 65 ± 10
Body mass index, kg/m2 25.8 ± 6.8
FEV1, liters 1.2 ± 0.6
FEV1%predicted 44.5 ± 19.3
FVC, liters 2.6 ± 0.9
FEV1/FVC 44.8 ± 11.9
paO2, mmHg 64.0 ± 9.7
paCO2, mmHg 40.6 ± 5.7
Modified MRC dyspnoea scale 1.9 ± 1.3
Six-minute walking distance, meter 303 ± 140
BODE index 4.3 ± 2.8
*Values are presented as mean ± standard deviation unless otherwise 
indicated.Respiratory Research 2009, 10:1 http://respiratory-research.com/content/10/1/1
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shown in table 2. The number of patients in stages I to IV
of COPD severity as defined by GOLD and the median
BODE index of the patients in each stage are shown in
table 3. The majority of patients had severe-to-very severe
COPD (stages III to IV). The median BODE index
increased from stage I to stage IV.
Symptoms of anxiety and depression
The mean anxiety score and the mean depression score
were 8.0 ± 4.3 and 7.8 ± 4.5, respectively. 60 patients
(49%) and 63 patients (52%) were found to have symp-
toms suggestive of anxiety and depression, respectively.
Anxious symptoms were more common in women (59%
in women versus 41% in men, p = 0.036). Presence of
depressive symptoms was independent of gender (51% of
the men; 52% of the women). FEV1%predicted was lower in
patients with anxious symptoms (40.5 ± 17.3) compared
to patients without (48.3 ± 20.5), mean difference -7.8,
95%CI -14.5 to -1.1; p = 0.025. FEV1%predicted was lower in
patients with depressive symptoms (37.0 ± 15.2) com-
pared to patients without (52.5 ± 20.0), mean difference -
15.5, 95%CI -21.8 to -9.2; p < 0.001. 78% of the patients
with anxious symptoms also had depressive symptoms
and 75% of the patients with depressive symptoms also
had anxious symptoms.
Anxiety and depression in COPD classified by GOLD or 
BODE
The anxiety score and the depression score correlated
closer with the BODE index (Kτ = 0.20, p = 0.001; Kτ =
0.41, p < 0.001; respectively) than with FEV1%predicted (Kτ =
-0.13, p = 0.037; Kτ = -0.28, p < 0.001; respectively). The
prevalence of anxiety increased with increasing BODE
stage (χ2 = 9.38, p = 0.002) but not with increasing GOLD
stages (χ2 = 3.29, p = 0.070). The prevalence of depression
increased with both increasing GOLD and BODE stages
(χ2 = 20.47, p < 0.001; χ2 = 32.84, p < 0.001). The preva-
lences of anxious and depressive symptoms within the
GOLD and BODE stages are shown in Figures 1 and 2.
The mean anxiety score in the GOLD stages I, II, III and IV
was 3.7 ± 2.6, 7.9 ± 4.2, 8.0 ± 4.1 and 8.6 ± 4.2, respec-
tively; p = 0.069. The mean depression score in the GOLD
stages I, II, III and IV was 1.5 ± 1.4, 6.7 ± 4.6, 7.8 ± 4.7 and
9.3 ± 4.5, respectively; p < 0.0001. The mean anxiety score
in the BODE stages I, II, III and IV was 6.3 ± 3.5, 7.7 ± 4.6,
9.5 ± 4.1 and 8.5 ± 4.6, respectively; p = 0.009. The mean
depression score in the BODE stages I, II, III and IV was
4.6 ± 3.1, 7.2 ± 4.3, 9.7 ± 3.4 and 10.9 ± 4.2, respectively;
p < 0.0001.
Association of the components of the BODE index with 
anxiety and depression
Linear regression was used to determine which compo-
nents of the BODE index were independently associated
with the anxiety and depression score. The six minute
walking distance and the MMRC dyspnoea scale were
independently associated with the depression score,
whereas the MMRC dyspnoea scale had a borderline sig-
nificant association with the anxiety score. (Table 4). After
removing the non-significant BMI and FEV1%predicted from
the regression equation and adjusting for the six-minute
walking distance the MMRC dyspnoea scale was signifi-
cantly associated with the anxiety score (MMRC dyspnoea
scale: β = 0.75, p = 0.043; six-minute walking distance: β =
-0.002, p = 0.497). FEV1%predicted and BMI were associated
with neither anxiety nor depression.
Discussion
This study demonstrates that anxious and depressive
symptoms are common in patients with advanced COPD.
The BODE index is superior to the GOLD classification for
explaining these symptoms. Anxious symptoms were
explained by dyspnoea. Depressive symptoms were
explained by both dyspnoea and reduced exercise capac-
ity.
COPD is increasingly considered as a disease not only of
the lungs. It has been suggested as a part of the 'chronic
systemic inflammatory syndrome' together with the met-
abolic syndrome, coronary artery disease and others [32].
The complexity of COPD and its frequent co-morbidities
requires assessment and staging of the disease beyond the
degree of airflow limitation. Using the hospital anxiety
Table 3: Classification of patients according to GOLD with the BODE index in each stage (n = 122); the BODE index is given as median 
and 1st to 3rd quartiles.
Severity of COPD according to GOLD Patients, N (%) BODE index
Stage I (FEV1 ≥ 80% predicted) 6 (5) 0 (0 to 0)
Stage II (50% ≤ FEV1 < 80% predicted) 39 (32) 1 (1 to 4)
Stage III (30% ≤ FEV1 < 50% predicted) 31 (25) 4 (3 to 6)
Stage IV (FEV1 ≤ 30% predicted) 46 (38) 7 (5 to 8)Respiratory Research 2009, 10:1 http://respiratory-research.com/content/10/1/1
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and depression score previous studies have yielded preva-
lences of anxious and depressive symptoms of up to 41%
and 44%, respectively in patients with COPD [6,9]. Our
findings confirm that both anxious and depressive symp-
toms are common in COPD and increase with disease
severity. The higher prevalence of anxious symptoms in
women is a known finding. Female COPD patients were
reported to suffer from psychiatric disorders and psycho-
logical distress more often than male patients [33].
We found that the degree of lung function impairment
cannot sufficiently explain anxious and depressive symp-
toms in COPD. This is in concordance with previous
research. FEV1%predicted was similar in patients with anxiety
or depression compared to patients without either prob-
lem in a study by Dahlen on patients with obstructive
lung disease [7]. Also, in a study by Ng on Singapore resi-
dent COPD patients FEV1%predicted alone was not able to
predict the presence of anxiety and depression [9]. In a
study by Mishima FEV1 did not correlate with the anxiety
score and had only a borderline correlation with the
depression score in COPD patients with long-term domi-
ciliary oxygen therapy [22]. In concordance with our find-
ings, dyspnoea correlated with both anxious and
depressive symptoms.
In our data BODE index better explained the psychologi-
cal consequences of COPD compared to the GOLD classi-
fication based on FEV1%predicted  alone. Due to the
incorporation of dyspnoea and exercise capacity the
BODE index is a reliable predictor of objective COPD out-
comes such as hospitalisation and survival [24,26]. On
the one hand severe dyspnoea and reduced exercise capac-
ity are obvious indicators for advanced lung disease. On
the other hand our data show that they are also associated
with symptoms of anxiety and depression, which them-
Prevalence of anxious and depressive symptoms in patients with COPD classified according to GOLD stages Figure 1
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selves are independent predictors of objective COPD out-
comes such as readmission and survival [6,7,9]. Therefore
anxiety and depression might explain a part of the predic-
tive power of the BODE index regarding objective COPD
outcomes. It is unknown whether anxiety and depression
remain independent predictors of clinical outcome of
COPD, if the disease is staged by the BODE system. If so,
these psychiatric co-morbidities might play a role in
future classification systems of COPD. Anxiety and
depression are aspects of COPD susceptible to both phar-
macological and non-pharmacological treatment [10].
Specifically, psychotherapy reduces anxiety and depres-
Prevalence of anxious and depressive symptoms in patients with COPD classified according to quartiles of the BODE index Figure 2
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Table 4: Linear regression of the components of the BODE index on the anxiety score and the depression score.
FEV1%predicted * 6 minute walking distance body mass index* MMRC dyspnoea score
β p β p β p β p
anxiety score -0.030 0.787 -0.083 0.472 0.126 0.167 0.222 0.067
depression score -0.090 0.346 -0.338 0.001 -0.016 0.837 0.227 0.031
* FEV1%predicted and Body mass index were logarithm transformed prior to regressionRespiratory Research 2009, 10:1 http://respiratory-research.com/content/10/1/1
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sion in COPD [34]. Moreover, pulmonary rehabilitation
improves depression, anxiety, dyspnoea and health status
in patients with COPD [35,36].
Due to the cross-sectional design of the present study only
associations can be assessed and causal inferences cannot
be drawn. The dyspnoea score was the only factor associ-
ated with anxious symptoms in linear regression. It is
quite evident that dyspnoea can cause anxiety. On the
other hand, presence of anxiety might also aggravate the
sensation of dyspnoea. Depressive symptoms were best
explained by the dyspnoea score and the six minute walk-
ing distance. It is well imaginable that patients who suffer
from breathlessness and whose exercise capacity is limited
are at increased risk of depression. On the other hand,
depressive symptoms might also worsen the sensation of
dyspnoea and limit the effort during the walking test.
Whether or not depression and anxiety are comorbidities
in COPD, they influence the clinical outcome of COPD
[6,7,9]. The small number of patients in GOLD stage I is a
limitation of the study. However, these patients usually
do not experience dyspnoea and are therefore unlikely to
have consecutive anxiety or depression.
Conclusion
In conclusion, anxious and depressive symptoms are com-
mon in patients with advanced COPD. The BODE index
is superior to the GOLD classification for explaining anx-
ious and depressive symptoms in COPD patients. Future
classifications of COPD severity might include those psy-
chological aspects, as they are potentially treatable aspects
of the disease.
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